Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts

Renier J. Brentjens,[1] Elmer Santos,[2] Yan Nikhamin,[1] Raymond Yeh,[1] Maiko Matsushita,[1] Krista La Perle,[3] Alfonso Quintás-Cardama,[1] Steven M. Larson,[2] and Michel Sadelain[1,4,5]

Abstract **Purpose:** Human T cells targeted to the B cell – specific CD19 antigen through retroviral-mediated transfer of a chimeric antigen receptor (CAR), termed 19z1, have shown significant but partial *in vivo* antitumor efficacy in a severe combined immunodeficient (SCID)-Beige systemic human acute lymphoblastic leukemia (NALM-6) tumor model. Here, we investigate the etiologies of treatment failure in this model and design approaches to enhance the efficacy of this adoptive strategy.

Experimental Design: A panel of modified CD19-targeted CARs designed to deliver combined activating and costimulatory signals to the T cell was generated and tested *in vitro* to identify an optimal second-generation CAR. Antitumor efficacy of T cells expressing this optimal costimulatory CAR, 19-28z, was analyzed in mice bearing systemic costimulatory ligand-deficient NALM-6 tumors.

Results: Expression of the 19-28z CAR, containing the signaling domain of the CD28 receptor, enhanced systemic T-cell antitumor activity when compared with 19z1 in treated mice. A treatment schedule of 4 weekly T-cell injections, designed to prolong *in vivo* T-cell function, further improved long-term survival. Bioluminescent imaging of tumor in treated mice failed to identify a conserved site of tumor relapse, consistent with successful homing by tumor-specific T cells to systemic sites of tumor involvement.

Conclusions: Both *in vivo* costimulation and repeated administration enhance eradication of systemic tumor by genetically targeted T cells. The finding that modifications in CAR design as well as T-cell dosing allowed for the complete eradication of systemic disease affects the design of clinical trials using this treatment strategy.

The majority of adult B-cell malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, and non – Hodgkin's lymphoma, are incurable despite currently available therapies. For this reason, novel therapeutic strategies are needed to treat these diseases. Adoptive therapy with genetically engineered autologous T cells is one such approach. T cells may be modified to target tumor-associated antigens through the introduction of genes encoding artificial T-cell receptors, termed chimeric antigen receptors (CAR), specific to such antigens (1 – 5).

CD19 is an attractive target for immune-mediated therapies as it is expressed on most B-cell malignancies and normal B cells, but not on bone marrow stem cells. We previously constructed a "first-generation" CAR, termed 19z1, specific to the CD19 antigen. The 19z1 CAR contains a CD19-specific murine single-chain fragment length antibody (scFv) fused to the extracellular and transmembrane regions of CD8, which, in turn, is fused to the intracellular signaling domain of the CD3 ζ chain. Human T cells retrovirally transduced to express the 19z1 receptor specifically lyse heterologous and autologous $CD19^+$ human tumor cells *in vitro* (6). A single i.v. injection of $19z1^+$ T cells into SCID-Beige mice bearing established systemic Raji tumor, a human Burkitt lymphoma tumor cell line that expresses the costimulatory ligands CD80 and CD86, successfully eradicates disease in 50% of mice (6). Unfortunately, a similar therapy fails to fully eradicate systemic NALM-6 tumor, a human pre-B cell ALL cell line that lacks expression of both CD80 and CD86. However, $19z1^+$ T-cell therapy of SCID-Beige mice bearing systemic NALM-6 tumors genetically engineered to express CD80 (NALM-6/CD80) enhanced long-term survival and resulted in complete NALM-6/CD80 tumor eradication in 40% of mice (6). Although these data show a role for *in vivo* costimulation in tumor eradication by genetically modified

Authors' Affiliations: Departments of [1]Medicine and [2]Radiology; [3]Research Animal Resource Center; [4]Immunology Program; and [5]Gene Transfer and Somatic Cell Engineering Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York

Received 3/23/07; revised 5/17/07; accepted 5/23/07.

Grant support: CA95152, CA59350, CA08748, CA86438, and CA96945; The Alliance for Cancer Gene Therapy (M. Sadelain); The Annual Terry Fox Run for Cancer Research (New York, NY) organized by the Canada Club of New York, William H. Goodwin and Alice Goodwin, and the Commonwealth Cancer Foundation for Research and the Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center (R.J. Brentjens and M. Sadelain); Amgen Career Development Award (R.J. Brentjens); and the Bocina Cancer Research Fund.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Renier J. Brentjens, Department of Medicine, Memorial Sloan Kettering Cancer Center, Box 242, 1275 York Avenue, New York, NY 10021. Phone: 212-639-7053; E-mail: brentjer@mskcc.org.

©2007 American Association for Cancer Research.

doi:10.1158/1078-0432.CCR-07-0674

Downloaded from http://aacrjournals.org/clincancerres/article-pdf/13/18/5426/1972030/5426.pdf by guest on 17 July 2022

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

tumor-targeted T cells, they neither fully explain the etiologies of treatment failure in a majority of treated mice nor provide a strategy to overcome these limitations.

To further investigate the *in vivo* limitations of this adoptive T-cell strategy, we chose to pursue the treatment of NALM-6 tumors in SCID-Beige mice due to the fact that the tumor in this model has several features that mimic B-cell ALL disease in human subjects: First, the disease is systemic; second, similar to the clinical setting, NALM-6 tumor displays an anatomic disease pattern that includes involvement of the bone marrow and central nervous system (CNS; ref. 7); and third, the NALM-6 tumor cell line fails to express costimulatory ligands as do most B-cell leukemias, including B-cell ALL. In this report, we use this NALM-6 tumor model to address the limitation of failed *in vivo* T-cell costimulation, and further investigate T-cell persistence and homing as potential etiologies of treatment failure. We found that both *in vivo* costimulation as well as repeated T-cell administration were critical to the complete eradication of NALM-6 tumor in SCID-Beige mice. Subsequent modifications in our treatment strategy based on these findings resulted in a markedly improved rate of complete tumor eradication in treated mice.

To our knowledge, this is the first report demonstrating complete eradication of a systemic human tumor lacking costimulatory ligands using genetically targeted T cells. Furthermore, complete eradication is achieved in the absence of further *in vivo* therapy, including prior chemotherapy or subsequent cytokine support. These optimized treatment strategies are likely to be applicable to future human trials enrolling patients with B-cell malignancies, including B-cell ALL.

Materials and Methods

Cell lines and T cells. Raji and NALM-6 tumor cell lines were cultured in RPMI 1640 (Life Technologies) supplemented with 10% heat-inactivated FCS, nonessential amino acids, HEPES buffer, pyruvate, and BME (Life Technologies). PG-13 and gpg29 retroviral producer cell lines were cultured in DMEM (Life Technologies) supplemented with 10% FCS, and NIH-3T3 artificial antigen-presenting cells (AAPC), described previously (6), were cultured in DMEM supplemented with 10% heat-inactivated donor calf serum. All media were supplemented with 2 mmol/L L-glutamine (Life Technologies), 100 units/mL penicillin, and 100 μg/mL streptomycin (Life Technologies). Where indicated, medium was supplemented with 10 ng/mL interleukin 15 (IL-15; R&D Systems).

Construction of second-generation CAR fusion genes. Construction of the 19z1 and Pz1 scFv-ζ chain fusion proteins have been previously published (6, 8). The resulting fusion genes were cloned into the SFG retroviral vector (9). VSV-G pseudotyped retroviral supernatants derived from transduced gpg29 fibroblasts were used to construct stable PG-13 gibbon ape leukemia virus (GaLV) envelope-pseudotyped retroviral producing cell lines using polybrene (Sigma) as described previously (8). All second-generation fusion receptors contain the scFv derived from 19z1. Human CD28, DAP10, 4-1BB, and OX40 coding regions were PCR amplified from a human activated T-cell cDNA library, and subcloned into the TopoTA PCR 2.1 cloning vector (Invitrogen). All receptor constructs were generated using overlapping PCR. The resulting cassettes were designed to facilitate the exchange of the transmembrane and signaling domains of the 19z1 construct by *Not*I/*Bam*HI restriction sites encoded in flanking primers.

Retroviral transduction and expansion of human T lymphocytes. Retroviral transduction of healthy donor T cells, obtained under institutional review board–approved protocol 90-095, is described elsewhere (8). For *ex vivo* expansion studies and cytokine release assays, transduced T cells were cocultured for 7 days after retroviral transduction in 24-well tissue culture plates (Falcon, Becton Dickinson) with confluent NIH 3T3 AAPCs in RPMI medium supplemented with 10% FCS, L-glutamine, streptomycin, and penicillin, with no added cytokines. For *in vivo* experiments, transduced T cells were injected after expansion on 3T3(CD19/CD80) or, for the Pz1$^+$ T cell control, 3T3[prostate-specific membrane antigen (PSMA)/CD80] AAPCs in RPMI medium as above, supplemented with 20 IU IL-2/mL and 10 ng/mL IL-15. For mice treated with multiple injections of modified T cells for 4 weeks, CAR$^+$ T cells were generated by weekly restimulation on AAPCs as described above.

Western blot analysis. Western blot analysis of T-cell lysates under reducing conditions with 0.1 mol/L DTT (Sigma) was done as previously described (10). Briefly, transduced T cells were washed in PBS and resuspended in radioimmunoprecipitation assay buffer (Boston Bioproducts) with mini complete protease inhibitor as per the manufacturer's instructions (Roche Diagnostics). Resulting proteins were separated on 12% SDS-PAGE mini gels (Bio-Rad) after the addition of 6× reducing loading buffer (Boston Bioproducts) and heating at 100°C for 10 min. Separated proteins were subsequently transferred to Immobilon membranes and probed using an anti-human CD3 ζ chain monoclonal antibody (BD Biosciences). Antibody binding was detected by probing the blot with goat anti-mouse horse radish peroxidase–conjugated antibody followed by luminescent detection using Western Lighting Chemiluminescence Reagent Plus (Perkin-Elmer Life Sciences) as per the manufacturer's instructions.

Cytotoxicity assays. We determined the cytotoxic activity of transduced T cells by standard ^{51}Cr release assays as described elsewhere (8). Briefly, transduced T cells were assessed by fluorescence-activated cell sorting analysis for CAR expression as well as CD4:CD8 ratio on day 4 after transduction. NALM-6 tumor cells were labeled with ^{51}Cr for 1 h at 37°C, washed with RPMI medium supplemented with 10% FCS, and resuspended in the same medium at a concentration of 1×10^5 tumor cells/mL. Transduced T cells were added to tumor cells at varying effector to target cell ratios in 96-well tissue culture plates in a final volume of 200 μL, and incubated for 4 h at 37°C. Thereafter, 30 μL of supernatant from each well was analyzed using Lumaplate-96 microplates (Packard Bioscience) by a Top Count NXT microplate scintillation counter (Packard Bioscience). Effector cell number in all assays was calculated based on the total number of CD8$^+$ CAR$^+$ T cells.

Cytokine detection assays. Cytokine assays were done per manufacturer's specifications using the multiplex Human Cytokine Detection System (Upstate, Inc.). Luminescence was assessed using the Luminex IS100 system and analyzed for cytokine concentration using IS 2.2 software (Luminex Corp.).

Flow cytometry. We did flow cytometry using a FACScan cytometer with Cellquest software (BD Biosciences). Cells were labeled with either phycoerythrin-conjugated, CAR-specific polyclonal goat antibody (Caltag Laboratories) or phycoerythrin-labeled anti-human CD8 and FITC-labeled anti-human CD4 monoclonal antibodies (Caltag Laboratories).

Retroviral transduction of NALM-6 tumor cells with GFP-FFLuc. The *GFP-FFLuc* gene (Clontech Laboratories) was subcloned into the SFG retroviral vector. VSV-G pseudotyped retroviral supernatants derived from gpg29 fibroblasts transduced with the resulting SFG (GFP-FFLuc) plasmid were used to transduce NALM-6 tumor cells as described elsewhere (10). Resulting tumor cells were sorted by fluorescence-activated cell sorting for GFP expression.

In vivo *SCID-Beige mouse tumor models.* We inoculated 8- to 12-week-old FOX CHASE C.B-17 (SCID-Beige) mice (Taconic) with tumor cells by tail vein injection. We subsequently treated mice by tail vein injection with transduced T cells. In the Raji tumor model, mice were injected by tail vein with 5×10^5 Raji tumor cells on day 1, and on day 6 were treated with a single i.v. dose of 1×10^7 CAR$^+$ T cells. In the NALM-6 upfront treatment tumor model, mice were injected by tail vein on day 1 with 1×10^6 NALM-6 tumor cells, and on days 2 to 4 were injected i.v. with 1×10^7 CAR$^+$ T cells daily. In the weekly

Downloaded from http://aacrjournals.org/clincancerres/article-pdf/13/18/5426/1972030/5426.pdf by guest on 17 July 2022

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

treatment model, mice were inoculated with NALM-6 tumor cells on day 1, and subsequently treated with i.v. injections of 1×10^7 CAR⁺ T cells on days 2, 8, 15, and 22. In all experiments, mice that developed hind limb paralysis or decreased response to stimuli were sacrificed by CO_2 asphyxiation. All murine studies were done in the context of an Institutional Animal Care and Use Committee–approved protocol (no. 00-05-065).

In vivo *bioluminescence of NALM-6 tumors.* Bioluminescence imaging was done using Xenogen IVIS Imaging System (Xenogen) with Living Image software (Xenogen) for acquisition of imaging data sets. Mice were infused by i.p. injection with 150 mg/kg D-luciferin (Xenogen) suspended in 200 μL PBS. Ten minutes later, mice were imaged while under 2% isoflurane anesthesia. Image acquisition was done on a 15- or 25-cm field of view at medium binning level for 0.5- to 3-min exposure time. Both dorsal and ventral views were obtained on all animals. Tumor bulk, as determined by IVIS imaging, was assessed as described previously (11).

Histologic analysis of mouse tissue sections. Mouse tissues were fixed in 10% buffered formalin phosphate (Fisher Scientific). Osseous samples (head with brain, vertebral column with spinal cord, and hind limbs) were fixed and decalcified in SurgiPath Decalcifier I (SurgiPath Medical Industries) as per the manufacturer's specifications. All tissues were processed by routine methods and embedded in paraffin wax. Five-micrometer sections were stained with H&E (Poly Scientific).

Statistics. Statistical analysis of survival data by log-rank analysis was obtained using GB-STAT software (Dynamic Microsystems).

Results

Construction of second-generation costimulatory CARs. We have previously shown that T cells which express the first-generation 19z1 CAR successfully eradicate systemic CD80/CD86⁺ Raji tumor in SCID-Beige mice. However, in the same report, we further show the inability of 19z1⁺ T cells to fully eradicate systemic NALM-6 tumors, which fail to express the costimulatory CD80 and CD86 ligands. The genetic modification of NALM-6 tumors to express CD80 allowed for the complete eradication of tumor in a significant number of treated mice (6) consistent with the notion that *in vivo* T-cell costimulation enhances the antitumor efficacy of tumor-specific T cells.

Because most B-cell tumors fail to express costimulatory ligands, we addressed this limitation of our treatment strategy by constructing a series of second-generation CARs designed to deliver an additional costimulatory signal in the absence of exogenous costimulatory ligand by inserting the transmembrane and cytoplasmic signaling domains of the CD28, DAP10, and 4-1BB costimulatory receptors into the 19z1 CAR (Fig. 1A). Alternative DAP-10– and 4-1BB–containing receptors, as well as the OX-40–containing CAR, were designed to contain the CD8 transmembrane domain from the original 19z1

Downloaded from http://aacrjournals.org/clincancerres/article-pdf/13/18/5426/1972030/5426.pdf by guest on 17 July 2022



Fig. 1. T-cell expression of second-generation CARs. *A,* pictorial representations of 19z1 with second-generation CAR genes demonstrating the genetic fragments used to generate the costimulatory CARs. *B,* Western blot analysis of T cells retrovirally transduced with CAR genes under reducing conditions. Membranes were probed with a monoclonal antibody specific to the cytoplasmic domain of the human ζ chain and show the expression of CARs at the expected molecular weights. The native T-cell ζ chain is indicated. Lane 1, 19z1; lane 2, 19-28z; lane 3, 19(DAPic)z; lane 4, 19z(DAPic); lane 5, 19(DAP)z; lane 6, 19(4-1BBic)z; lane 7, 19(4-1BB)z; and lane 8, 19(OX-40ic)z. *C,* NALM-6 tumor lysis by CAR⁺ T cells was assessed by standard 4 h ^{51}Cr release assays. All T cells expressing CD19-targeted second-generation CARs lysed target tumor cells equally well when compared with T cells expressing the first-generation 19z1 CAR. Control T cells expressing the irrelevant Pz1 CAR did not significantly lyse NALM-6 tumors. Effector to target ratios (*E:T Ratio*) represent T cells normalized to the CD8⁺ CAR⁺ T-cell fraction. Data represent one of three different experiments using three different healthy donor T-cell populations with similar results.

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.



Fig. 2. *In vitro* T-cell costimulation of CAR+ T cells as assessed by proliferation and cytokine secretion after coculture on NIH 3T3 fibroblast AAPCs. *A,* CAR-transduced T cells, normalized to the CAR+ T-cell fraction, were cocultured on AAPC monolayers either without exogenous costimulation [3T3(CD19); *left*], or with exogenous costimulation [3T3(CD19/CD80); *right*]. On day 1, 5×10^5 CAR+ T cells were cocultured on AAPC monolayers in 24-well tissue culture plates in cytokine-free medium. On days 4 and 7, total viable T-cell counts were obtained by trypan blue exclusion assays, and FACS analysis was done on these samples to calculate the total number of CAR+ T cells. Whereas 19-28z, 19(4-1BB)z, and 19(4-1BBic)z transduced T cells expanded by day 4, only 19-28z+ T cells continued to expand in the absence of exogenous CD80 costimulation (*left*). Control Pz1+ T cells failed to expand in either setting. *B* and *C,* equal numbers of CAR+ T cells were incubated in the absence of additional cytokines AAPC monolayers. Cell-free tissue culture supernatants were analyzed at 24 h after coculture for the presence of cytokines: lane 1, 19z1; lane 2, 19-28z; lane 3, Pz1; lane 4, 19(DAP)z; lane 5, 19(DAPic)z; lane 6, 19z(DAPic); lane 7, 19(OX-40ic)z; lane 8, 19(4-1BB)z; and lane 9, 19(4-1BBic)z. Only T cells that expressed the 19-28z CAR secreted significant levels of IL-2 (*B*) and IFNγ (*C*) in the absence of exogenous CD80. These data are representative of one of three different experiments using three different healthy donor T-cell populations, all of which showed the same proliferation and cytokine secretion patterns.

construct to assess whether this CAR design could enhance costimulatory signaling. Finally, we also assessed whether placing the DAP-10 signaling domain either proximal or distal to the ζ chain signaling domain improved CAR function.

T cells from healthy human donors were retrovirally transduced to express these CAR constructs. T-cell transduction efficiency, as assessed by flow cytometric analysis, ranged from 50% to 80% (data not shown). Western blot analysis of transduced T cells, normalized to the CAR+ fraction, showed comparable levels of CAR proteins present at the predicted molecular weights (Fig. 1B).

To verify that second-generation CARs when expressed in human T cells retained the ability to lyse CD19+ tumor cells *in vitro*, we conducted standard 4 h ^{51}Cr release assays using transduced healthy donor T cells targeting ^{51}Cr-labeled CD19+ NALM-6 tumor cells (Fig. 1C). Effector to target ratio between different CAR constructs was normalized to the CD8+ CAR+ T-cell population. All tested CARs, with the exception of the Pz1+ T-cell control, specific to the PSMA, were able to mediate tumor cell lysis equally well when compared with the first-generation 19z1 CAR.

Characterization of second-generation CAR costimulatory function. We have previously generated a series of AAPCs derived from NIH-3T3 murine fibroblasts genetically engineered to express either CD19 alone [3T3(CD19)] or both CD19 and CD80 [3T3(CD19/CD80); ref. 6]. When cocultured

Downloaded from http://aacrjournals.org/clincancerres/article-pdf/13/18/5426/1972030/5426.pdf by guest on 17 July 2022

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

with CD19-specific CAR⁺ T cells, the former [3T3(CD19)] provides T cells with a CAR-mediated activation signal (signal 1) alone, whereas the latter [3T3(CD19/CD80)] provides T cells with signal 1 as well as an exogenous costimulatory signal (signal 2) mediated through CD80 on the AAPC binding to CD28 on the T cell.

To assess CAR-mediated T-cell proliferation, transduced T cells were cocultured on both 3T3(CD19) and 3T3(CD19/CD80) AAPCs in the absence of exogenous cytokine. CAR^+ T-cell number was determined after coculture on 3T3(CD19) and 3T3(CD19/CD80) AAPCs (Fig. 2A) on days 4 and 7. Following coculture on 3T3(CD19) AAPCs, only T cells transduced with the 19-28z, 19(4-1BB)z, and 19(4-1BBic)z CARs expanded after 4 days of coculture, whereas at day 7, only T cells transduced with the 19-28z CAR had undergone significant proliferation (10-fold expansion) consistent with CAR-mediated T-cell costimulation. All other constructs failed to promote T-cell proliferation in the absence of exogenous costimulation. Significantly, 19-28z CAR^+ T cells proliferated equally well on either 3T3(CD19) or 3T3(CD19/CD80) AAPCs, and proliferated equally well when compared with $19z1^+$ T cells in the setting of 3T3(CD19/CD80) AAPC stimulation.

We next assessed CAR^+ T-cell secretion of IL-2 and IFN-γ as surrogate makers of costimulation. Equal numbers of CAR^+ T cells with similar CD4:CD8 ratios were cocultured on 3T3(CD19) and 3T3(CD19/CD80) AAPCs in cytokine-free medium after initial T-cell transduction. At 24 h after T-cell coculture on AAPCs, tissue culture supernatants were analyzed for the presence of IL-2 and IFN-γ. Coculture of $19\text{-}28z^+$ T cells on 3T3(CD19) AAPCs resulted in significantly elevated levels of IL-2 (Fig. 2B) and IFN-γ (Fig. 2C) when compared with the first-generation 19z1 CAR as well as the other six tested second-generation CARs. These data further confirm the ability of the 19-28z CAR to elicit a costimulatory signal independent of exogenous costimulatory ligand. Significantly, 4-1BB and DAP-10 constructs containing either the native or CD8 transmembrane domains showed no significant differences in function, and in the setting of the DAP-10 constructs, no differences in function were observed when the signaling domain was placed either proximal or distal to the ζ chain.

In vivo *antitumor activity of alternative costimulatory CARs.* To define the *in vivo* costimulatory activity of the 19-28z CAR, we initially compared the antitumor activity of $19z1^+$ and $19\text{-}28z^+$ T cells in a previously established systemic Raji tumor model. Because both $19z1^+$ T cells and $19\text{-}28z^+$ T cells are costimulated *in vivo* by $CD80/CD86^+$ Raji tumor cells, we predicted and observed equal long-term survival (50%) in both treatment groups (Fig. 3A). We next compared the same treatment groups (19z1 versus 19-28z) in mice bearing systemic NALM-6 tumor, which fails to express the CD80 and CD86 costimulatory ligands. We observed improved antitumor efficacy in the 19-28z treatment group (Fig. 3B). However, the improved long-term overall survival was modest (0 of 15 $19z1^+$ T cell–treated mice versus 3 of 17 or 18% of $19\text{-}28z^+$ T cell–treated mice; $P < 0.03$). Treatment with $19(4\text{-}1BB)z^+$ and $19(4\text{-}1BBic)z^+$ T cells enhanced survival when compared with mice treated with the control $Pz1^+$ T cells, but overall survival was similar to $19z1^+$ T cell–treated mice, with no long-term surviving mice (data not shown). Fluorescence-activated cell sorting analysis of single-cell suspensions of tissues derived from mice that failed $19\text{-}28z^+$ T cell treatment showed persistent expression of CD19 on the tumor cells, ruling out the possibility that down-regulation of the CD19 target antigen was a source of treatment failure (data not shown).

Repeated administration of CD19-targeted T cells enhances complete NALM-6 tumor eradication. Using bioluminescent imaging of treated SCID-Beige mice bearing NALM-6(GFP-FFLuc) tumors, we found a 10- to 14-day delay of tumor progression after $19z1^+$ T-cell therapy when compared with $Pz1^+$ T-cell therapy (Fig. 4A-B). A similar delay of tumor progression was seen after $19\text{-}28z^+$ T-cell therapy in mice with relapsed disease (data not shown). Fluorescence-activated cell sorting analysis of single-cell suspensions derived from tissues of $19\text{-}28z^+$ T cell–treated tumor-bearing mice confirmed a

Downloaded from http://aacrjournals.org/clincancerres/article-pdf/13/18/5426/1972030/5426.pdf by guest on 17 July 2022



Fig. 3. *In vivo* analysis of CD19-specific CAR^+ T cells in SCID-Beige mice bearing systemic human $CD19^+$ tumors. *A,* treatment with $19z1^+$ or $19\text{-}28z^+$ T cells eradicated systemic Raji tumors in SCID-Beige mice equally well. Briefly, mice were injected by tail vein with 5×10^5 Raji tumor cells on day 1. Mice were subsequently treated with a single dose of 1×10^7 CAR^+ T cells by tail vein injection on day 6. Mice treated with either $19z1^+$ or $19\text{-}28z^+$ T cells eradicated tumor equally well with an overall 50% long-term survival in both treatment groups. *B,* treatment of NALM-6 bearing SCID-Beige mice with $19\text{-}28z^+$ T cells (1×10^7 CAR^+ T cells injected daily × 3 d) statistically enhanced survival when compared with similar treatment with $19z1^+$ T cells (18% versus 0% long-term survival; $P < 0.03$).

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

WHAT WILL YOU BUILD? | sales@docketalarm.com | 1-866-77-FASTCASE

fastcase® Smarter legal research.